Bispecific T-cell engaging antibodies for cancer therapy

Cancer Research

Volumn 69, Issue 12, 2009, Pages 4941-4944

  Baeuerle, Patrick A ^a,b   Reinhardt, Carsten ^a  

^a Micromet Inc   (United States)

^b MICROMET AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGER ANTIBODY; BLINATUMOMAB; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CD3 ANTIGEN; CD33 ANTIGEN; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; MT 103; MT 110; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DISORIENTATION; DOSE RESPONSE; DRUG EFFICACY; FEVER; FOLLICULAR LYMPHOMA; HUMAN; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPEECH DISORDER; TUMOR CELL; TUMOR GROWTH;

ANTIBODIES, BISPECIFIC; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 67449156132     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0547     Document Type: Review

References (22)

1. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-631 (Pubitemid 15080840)
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129 (Pubitemid 33741887)
3. Kontermann RE, Müller D. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007;9:319-326 (Pubitemid 47255664)
4. Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997;45:210-215 (Pubitemid 27521462)
5. Bird RE, Walker BW. Single chain antibody variable regions. Trends Biotechnol 1991;9:132-137 (Pubitemid 121003095)
6. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995;92:7021-7025
7. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-697 (Pubitemid 34832980)
8. Brischwein K, Parr L, Pflanz S, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807. (Pubitemid 350295358)
9. Baeuerle PA, Reinhardt C, Kufer P. BiTE: A new class of antibodies that recruit T cells. Drugs Future 2008;33:137-147
10. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T cells for cancer therapy. Curr Opin Mol Ther 2009;11:22-30.
11. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977
12. Topp M, Goekbuget N, Kufer P, et al. Treatment with anti-CD19 BiTE antibody blinatumomab (MT103/MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lmphoblastic leukemia (ALL): First results of ongoing phase 2 study [ASH Annual Meeting Abstract]. Blood 2008;112:1926.
13. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-1143 (Pubitemid 43063166)
14. Maetzel D, Denzel S, Mack B, et al: Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. Published Online 2009 Jan 11.
15. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predicts clinical outcome. Science 2006;313:1960-1964 (Pubitemid 44498003)
16. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-397 (Pubitemid 46225341)
17. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-296 (Pubitemid 46697910)
18. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008;14:4385-4391
19. Langer LF, Clay TM, Morse MA. Update on CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245-1256 (Pubitemid 47305249)
20. Meidenbauer N, Zippelius A, Pittet MJ, et al. High frequency of functionally active Melan-A-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004;64:6319-6326 (Pubitemid 39129437)
21. Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-453
22. Boissonnas A, Fether L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204:345-356